The study, called «Molecular Determinants of Drug - Specific Sensitivity for
Epidermal Growth Factor Receptor (EGFR) Exon 19 and 20
Mutants in Non-Small Cell Lung Cancer,» and published online in the journal Oncotarget, demonstrates how computer modeling of EGFR mutations found in lung cancer can elucidate their molecular mechanism of action and consequently optimize the selection of therapeutic agents to treat patients.